Invion Ltd (ASX: IVX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Invion Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Invion Ltd (ASX: IVX)
Latest News
Share Gainers
This small-cap ASX healthcare stock just exploded 131%! Here's why
Healthcare Shares
Invion share price (ASX:IVX) rockets 123% on pilot study results
Share Gainers
Why the Invion share price rocketed 225% higher today
Share Gainers
Why the Invion share price zoomed 86% higher today
⏸️ Investing
Here's why Invion Ltd stock plunged 24.4% today
IVX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Invion Ltd
Invion Ltd is an Australian clinical-stage pharmaceutical drug development company. It is engaged in the development of PhotoDynamic Therapy (PDT) for cancer treatments called Photosoft, for the treatment of a range of cancers, and infectious diseases. The company produces topical and intravenous products suitable for use in skin cancer and solid tumors, such as ovarian, prostate, and lung cancer. Invion has developed a portfolio of patent protected compounds. Its drug candidate is INV043, a novel photosensitiser which has the potential to work as a therapy and a diagnostic tool.
IVX Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 06 Feb 2026 | $0.09 | $0.00 | 0.00% | 39,449 | $0.09 | $0.09 | $0.08 |
| 05 Feb 2026 | $0.08 | $0.00 | 0.00% | 133,080 | $0.09 | $0.09 | $0.08 |
| 04 Feb 2026 | $0.08 | $0.00 | 0.00% | 20,723 | $0.08 | $0.08 | $0.08 |
| 03 Feb 2026 | $0.08 | $0.00 | 0.00% | 9,416 | $0.09 | $0.09 | $0.08 |
| 02 Feb 2026 | $0.08 | $-0.01 | -10.87% | 325,931 | $0.09 | $0.09 | $0.08 |
| 28 Jan 2026 | $0.09 | $0.00 | 0.00% | 92,942 | $0.09 | $0.09 | $0.09 |
| 27 Jan 2026 | $0.09 | $0.00 | 0.00% | 482 | $0.09 | $0.09 | $0.09 |
| 23 Jan 2026 | $0.09 | $0.00 | 0.00% | 110,368 | $0.09 | $0.09 | $0.09 |
| 21 Jan 2026 | $0.09 | $0.00 | 0.00% | 105,227 | $0.09 | $0.09 | $0.09 |
| 20 Jan 2026 | $0.09 | $0.00 | 0.00% | 202,617 | $0.09 | $0.09 | $0.09 |
| 19 Jan 2026 | $0.09 | $0.00 | 0.00% | 26,704 | $0.09 | $0.09 | $0.09 |
| 15 Jan 2026 | $0.09 | $0.00 | 0.00% | 82,957 | $0.09 | $0.09 | $0.09 |
| 14 Jan 2026 | $0.09 | $0.00 | 0.00% | 833 | $0.09 | $0.09 | $0.09 |
| 13 Jan 2026 | $0.09 | $0.00 | 0.00% | 72,189 | $0.09 | $0.09 | $0.09 |
| 12 Jan 2026 | $0.09 | $0.00 | 0.00% | 48,795 | $0.09 | $0.09 | $0.09 |
| 09 Jan 2026 | $0.09 | $0.00 | 0.00% | 2 | $0.09 | $0.09 | $0.09 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 23 Sep 2025 | Chiat Chew | Expiry | 1,384,886 | $152,337 |
Options expired.
|
| 23 Jul 2025 | Chiat Chew | Issued | 10,000,000 | $150,000 |
Rights issue.
|
| 18 Jul 2025 | Chiat Chew | Issued | 4,210,806 | $63,162 |
Rights issue.
|
| 18 Jul 2025 | Alan Yamashita | Issued | 115,541 | $1,733 |
Rights issue.
|
| 18 Jul 2025 | Alistair Bennallack | Issued | 181,064 | $2,715 |
Rights issue.
|
| 24 Jun 2025 | Alistair Bennallack | Buy | 37,647 | $4,705 |
Exercise of options.
|
| 24 Jun 2025 | Alistair Bennallack | Exercise | 37,647 | $4,705 |
Exercise of options.
|
| 24 Jun 2025 | Alan Yamashita | Buy | 41,411 | $5,176 |
Exercise of options.
|
| 24 Jun 2025 | Alan Yamashita | Exercise | 41,411 | $5,176 |
Exercise of options.
|
| 24 Jun 2025 | Chiat Chew | Buy | 68,086 | $8,510 |
Exercise of options.
|
| 24 Jun 2025 | Chiat Chew | Exercise | 68,086 | $8,510 |
Exercise of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Ms Melanie Jaye Leydin | Non-executive directorCompany Secretary | Aug 2024 |
Ms Leydin is now the Executive Vice President of Global Soultions, Southeast Asia at Vistra. Vistra is a provider of governance and compliance solutions and finance and accounting solutions in the Fund, Corporate, Capital Markets, and Private Wealth sectors. Melanie has over 20 years of experience holding Board positions including Company Secretary and CFO of ASX listed entities. Melanie has experience in relation to public company responsibilities, including ASX and ASIC compliance, control and implementation of corporate governance, statutory financial reporting, reorganization of Companies, initial public offerings, secondary raisings and shareholder relations.
|
| Mr Chiat Thian Chew | Chief Executive OfficerExecutive ChairmanExecutive Director | Dec 2017 |
Mr Chew has over 25 years of experience in healthcare biotech, investing and transforming business operations. He is also Co-Founder of Chronic Airway Therapeutics; a clinical stage firm focused on the treatment of respiratory diseases and Managing Partner at Polar Ventures. Thian is also an Advisory Board Member at Stanford Medicine's Center for Asian Health Research and Education (CARE). Prior to this, Thian was an Executive Director at Goldman Sachs (New York, Hong Kong), responsible for the firm's proprietary investments, and was a Consultant Project Manager at Morgan Stanley's Strategic Services Group (New York). He also held several positions in KPMG across Asia Pacific including Director at KPMG Consulting (Singapore and Sydney) where he led several large-scale operational restructurings, post-merger integration, transformation, and business performance improvement programs. As a Senior Manager at KPMG (Taipei and Melbourne), he led several business re-engineering initiatives, and performed financial and information technology audit, risk and assurance engagements across multiple industries. He is also Visiting Professor at UCL Global Business School for Health.
|
| Mr Alan Yamashita | Non-Executive Director | Feb 2019 |
Mr Yamashita is an experienced corporate consultant and investment professional, with over 40 years of experience in investment management, investment banking and alternative investment throughout the APAC region. From 1999 to 2005, Mr Yamashita was President and CEO of Search Investment Group and founding CEO and CIO of Search Alternative Investment Ltd (SAIL), a private global hedge fund and private equity investment practice headquartered in Asia. Prior to Search Investments Group, Mr Yamashita was Managing Director and Head of Asia Capital Markets for Merrill Lynch from 1996 to 1998. Mr Yamashita is currently Managing Partner at Polar Ventures and has held numerous positions as a 16-year veteran of Goldman Sachs and an advisor to various companies, including Plantation Timber Partners, Wuhan; Duty Free Shoppers, Asia; TVSN, Shanghai; and Mizuho Alternative Investments LLC. He is a Member of the Risk Committee.
|
| Mr Alistair Bennallack | Non-Executive Director | Oct 2020 |
Mr Bennallack is currently the Chief Operating Officer and Chief Financial Officer of Village Roadshow Pty Ltd. In this capacity he also has primary responsibility for the Group Risk function. In addition, he is also Chief Executive Officer of Village Roadshow Theme Parks Asia, a division of Village Roadshow Theme Parks Pty Ltd. He is the primary executive responsible for conceptualizing, executing and delivering Village Roadshow's expansion into China and Asia. He is a former member of the Village Roadshow Ltd Executive Committee, current member of the Village Roadshow Theme Parks Executive Committee and current member of all Village Roadshow Pty Ltd's Management and Risk Committees. His previous roles have included Chief Financial Officer of Village Roadshow Ltd and General Manager Business Affairs of Village Roadshow Corporation Pty Ltd (controlling shareholder of Village Roadshow Ltd.). He is Chair of the Risk Committee.
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Polar Ventures Limited | 5,452,178 | 8.20% |
| BNP Paribas Nominees Pty Noms Retail Client Drp> | 5,447,343 | 8.00% |
| RMWC Pty Ltd Rmwc Family A/C> | 3,142,372 | 4.70% |
| Surfit Capital Pty Ltd | 3,000,000 | 4.30% |
| Mr Honsue Cho | 2,846,265 | 4.10% |
| Ngpdt Greater China Limited | 2,726,523 | 4.10% |
| Mei Jun Lin | 2,725,000 | 3.40% |
| Citicorp Nominees Pty Limited | 2,468,145 | 3.00% |
| Ms Xiaoyi Wu Xiaoyi Wu Interactive Brokers A/C> | 2,000,000 | 2.70% |
| Acslnc Pty Ltd Acslnc Family A/C> | 1,928,000 | 2.70% |
| Shengli Wang | 1,362,881 | 2.30% |
| Ms Xiaoyi Wu Xiaoyi Wu Interactive Brokers A/C> i | 1,214,286 | 2.10% |
| Yong Chen | 1,100,000 | 1.80% |
| Mr Yong Chen | 932,531 | 1.70% |
| Zanya Nominees Pty Ltd Jls Superannuation A/C> | 917,744 | 1.40% |
| Ms Dandan Wang | 828,196 | 1.20% |
| Mr Shengwei Ou | 773,042 | 1.20% |
| Shubo Miao | 733,334 | 1.10% |
| Hunt Prosperity Pty Ltd Investius Pb Micro A/C> | 714,286 | 1.00% |
| Mr Esmond Wong & Mrs Quynh Thi Kim Nguyen | 675,648 | 0.90% |